Monthly Versus Two Doses of Ante-Natal Intermittent Preventive Treatment With Sulphadoxine-Pyrimethamine

• Status: Unknown status
• Trial end date: 2019-02-01
• Target enrollment: 0
• Participant gender: Female

Summary

Randomized controlled prospective comparative study

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University College Hospital, Ibadan
• Treatments: Fanasil, pyrimethamine drug combination; Pyrimethamine; Sulfadoxine

Criteria

Inclusion Criteria:

• Pregnant women

• Gestational age between 16 and 28weeks.

• No history of use of sulphadoxine-pyrimethamine prior to recruitment

• Not on any medication for prophylaxis

Exclusion Criteria:

• Anaemia

• HIV positive women

• Pre-existing medical conditions e.g diabetes mellitus, haemoglobinopathy, hypertension, kidney disease, heart disease, any endocrine disorder like hypo/hyperthyroidism, Cushing' disease, connective tissue disorders like systemic lupus erythematosus, antiphospholipid syndrome or any otherautoimmune disease with poor feto-maternal outcomes in pregnancy.

• History of Glucose -6-Phosphate Dehydrogenase (G6PD) deficiency in patient

• Allergy to sulphonamides or pyrimethamine.

• Non consenting patients

• Multiple gestations